In vitro high-throughput drug sensitivity screening with patient-derived primary cells as a guide for clinical practice in hepatocellular carcinoma—A retrospective evaluation

Li, Jinghe; Xiong, Xiu; Zuo, Wang; Zhao, Yufei; Shi, Zhonghua; Zhao, Ming; Ren, Tao

doi:10.1016/j.clinre.2020.01.003

Cited by 3 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For HEHDS-guided therapy, leukemia cells were cultured with complete medium (Precedo, Hefei, China) at 37°C in 5% CO 2 incubator. The high-throughput drug sensitivity screening was performed as previously reported [ 21 ]. To assess drug susceptibility, cell plating was carried out by counting cells in the logarithmic growth phase and then adding them in a white 384-well cell culture plate with a density of 1 × 10 5 cells/ml.…”

Section: Methodsmentioning

confidence: 99%

Application of High-Efficiency Cell Expansion and High-Throughput Drug Sensitivity Screening for Leukemia Treatment

Wang

et al. 2022

Disease Markers

View full text Add to dashboard Cite

This study is to assess the clinical value of in vitro primary cell high-efficiency expansion and high-throughput drug sensitivity screening (HEHDS) system in leukemia, and we evaluated a cohort of 121 patients with acute myeloid leukemia (AML) and 27 patients with acute lymphoblastic leukemia (ALL) using HEHDS. Bone marrow aspirates were collected from patients with leukemia. Purified leukemic cancer cells were obtained, cultured, and screened with a panel of 247 FDA-approved compounds by HEHDS technology. Ninety-six patients received HEHDS-guided therapy while 52 patients who were subjected to physician directed therapy served as controls. ALL patients who received treatment guided by HEHDS showed higher rate of complete remission (CR) than that of patients in the non-HEHDS group (90.91% vs. 56.25%). Similarly, AML patients received HEHDS-guided therapy were found to have greater CR rate, when compared with patients who received physician-directed therapy (45.88% vs. 25%). There was a significantly higher rate of CR in HEHDS-guided therapy group compared to the non-HEHDS group. The application of HEHDS could be beneficial for leukemia treatment.

show abstract

Section: Methodsmentioning

confidence: 99%

Application of High-Efficiency Cell Expansion and High-Throughput Drug Sensitivity Screening for Leukemia Treatment

Wang

et al. 2022

Disease Markers

View full text Add to dashboard Cite

show abstract

“…High-throughput drug sensitivity (HDS) screening strategy is a new method with the advantages of high efficiency, wide coverage, and potential adaptation to personalized therapy, which are promising for determining the antitumor drug sensitivity in liver cancer, head and neck cancer, and lymphomas (12)(13)(14). However, the application of this technique in antitumor drug screening of ESCC is rarely reported.…”

Section: Introductionmentioning

confidence: 99%

HDS screening with patient-derived primary cells guided individualized therapy for esophageal squamous cell carcinoma–in vivo and vitro

He¹,

Huang²,

et al. 2023

Front. Med.

View full text Add to dashboard Cite

ObjectiveTo analyze and evaluate the role of the High-throughput Drug Sensitivity (HDS) screening strategy in identifying highly sensitive drugs against esophageal squamous cell carcinoma (ESCC).MethodsA total of 80 patients with progressive ESCC were randomly divided into the observation (40 cases) and the control groups (40 cases). In the observation group, primary ESCC cells were isolated from the tumor tissues with a gastroscope, and drug sensitivity screening was performed on cells derived from the 40 ESCC cases using the HDS method, followed by verification in a patient-derived tumor xenograft (PDX) mouse model. Finally, the differences in the therapeutic efficacy (levels of CEA, CYFRA21-1, SCCA after chemotherapy and the rates of overall survival, local progression, and distant metastasis at 12 months and 18 months time points after chemotherapy) were compared between the observation group (Screened drug-treated) and the control group (Paclitaxel combined with cisplatin regimen-treated).ResultsForty ESCC patients were screened for nine different high-sensitive chemotherapeutics, with the majority showing sensitivity to Bortezomib. Experiments on animal models revealed that the tumor tissue mass of PDX mice treated with the HDS-screened drug was significantly lower than that of the Paclitaxel-treated mice (p < 0.05), and the therapeutic efficacy of the observation group was better than the control group (p < 0.05).ConclusionHDS screening technology can be beneficial in screening high-efficacy anticancer drugs for advanced-stage ESCC patients, thereby minimizing adverse drug toxicity in critically ill patients. Moreover, this study provides a new avenue for treating advanced ESCC patients with improved outcomes.

show abstract

“…This method allows the simultaneous screening of 100–1,000 drugs, with a wide screening range (covering all drugs approved by the FDA), and can thus provide comprehensive drug testing and precise treatment for patients with early/middle/late-stage cancer in a short period of time. A previous study [ 12 ] showed that HDS was a safe and reliable method for helping to select postoperative adjuvant chemotherapy drugs for liver cancer patients, compared with empirical chemotherapy; however, this approach is still not widely used in clinical practice. In this study, we examined the HDS results for several cytotoxic and targeted drugs and chemotherapy regimens in relation to the immunohistochemical characteristics of liver cancer cells, to identify possible correlations as a reference for clinical treatment.…”

Section: Introductionmentioning

confidence: 99%

Correlation between Immunohistochemical Markers in Hepatocellular Carcinoma Cells and In Vitro High-Throughput Drug Sensitivity Screening

Feng

Cheng

Chen

et al. 2022

Canadian Journal of Gastroenterology and Hepatology

View full text Add to dashboard Cite

Aim. This study analyzed the correlation between immunohistochemical markers in hepatocellular carcinoma cells and the results of in vitro high-throughput drug sensitivity screening, to provide a reference for individualized drug treatment in patients with liver cancer. Methods. Seventy-four patients with hepatocellular carcinoma were included in this study from December 2019 to June 2021, and their liver cancer cells were used for in vitro high-throughput drug sensitivity screening. According to the screening results, the patients were divided into relatively sensitive and insensitive groups, and the correlations between sensitivity and immunohistochemistry results were analyzed statistically. Results. Alpha-fetoprotein (AFP)-positive liver cancer cells were significantly more sensitive to gemcitabine than AFP-negative cells (χ2 = 6.102, P = 0.014 ). AFP was also positively correlated with sensitivity of liver cancer cells to three combined regimens containing oxaliplatin (L-OHP) and epirubicin (EPI) : L-OHP + EPI + irinotecan + 5-fluorouracil (5-FU), L-OHP + irinotecan + EPI, and L-OHP + EPI (χ2 = 8.168, P = 0.004 , χ2 = 5.705, P = 0.017 , and χ2 = 8.275, P = 0.004 , respectively). Conclusion. Gemcitabine and L-OHP + EPI + irinotecan + 5-FU, L-OHP + EPI, and L-OHP + irinotecan + EPI were more effective against AFP-positive compared with AFP-negative liver cancer cells according to in vitro high-throughput drug sensitivity screening. These results may guide the selection of personalized drug treatments for patients with advanced liver cancer in the future but still need further clinical studies to confirm.

show abstract

In vitro high-throughput drug sensitivity screening with patient-derived primary cells as a guide for clinical practice in hepatocellular carcinoma—A retrospective evaluation

Cited by 3 publications

References 29 publications

Application of High-Efficiency Cell Expansion and High-Throughput Drug Sensitivity Screening for Leukemia Treatment

Application of High-Efficiency Cell Expansion and High-Throughput Drug Sensitivity Screening for Leukemia Treatment

HDS screening with patient-derived primary cells guided individualized therapy for esophageal squamous cell carcinoma–in vivo and vitro

Correlation between Immunohistochemical Markers in Hepatocellular Carcinoma Cells and In Vitro High-Throughput Drug Sensitivity Screening

Contact Info

Product

Resources

About